Abstract
Background:
Individuals who reach exceptional longevity (100+ years of age) free of common chronic age diseases (i.e. ‘dodgers’) arguably represent the paradigm of successful aging in humans. As such, identification of potential biomarkers associated with this phenomenon is of medical interest.
Methods:
We measured serum levels of galectin-3 and osteopontin, both of which have been shown to be linked with major chronic or aging-related disorders in younger populations, in centenarian ‘dodgers’ (n=81; 40 men; 100–104 years) and healthy controls (n=41; 24 men, 70–80 years).
Results:
Both biomarkers showed significantly lower values (p<0.001) in the former (galectin-3: 2.4±1.7 vs. 4.8±2.8 ng/mL; osteopontin: 38.1±27.7 vs. 72.6±33.1 μg/mL). Logistic regression analysis identified the combination of these two biomarkers as a significant predictor variable associated with successful aging regardless of sex (p<0.001). The area under the curve (AUC) classified the ability of galectin-3 and osteopontin to predict the likelihood of successful aging as ‘fair’ (AUC=0.75) and ‘good’ (AUC=0.80), respectively. Particularly, the combination of the two biomarkers showed good discriminatory power for successful aging (AUC=0.86), with sensitivity=83% and specificity=74%.
Conclusions:
Lower levels of both galectin-3 and osteopontin are associated with successful aging, representing potential biomarkers of this condition. Our cross-sectional data must be however approached with caution. Further research is necessary to replicate the present preliminary results in other cohorts and to identify the potential use of galectin-3 and osteopontin as potential targets (or at least predictors) in future personalized anti-aging therapies.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: Research in the field of aging by A. Lucia is funded by Fondo de Investigaciones Sanitarias (FIS, grant #PI15/00558) and Fondos Feder.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. McCullough PA. Practical experience using galectin-3 in heart failure. Clin Chem Lab Med 2014;52:1425–31.10.1515/cclm-2014-0278Search in Google Scholar PubMed
2. Filipe MD, Meijers WC, Rogier van der Velde A, de Boer RA. Galectin-3 and heart failure: prognosis, prediction and clinical utility. Clin Chim Acta 2015;443:48–56.10.1016/j.cca.2014.10.009Search in Google Scholar PubMed
3. Lippi G, Cervellin G. Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers. Crit Rev Clin Lab Sci 2014;51:13–29.10.3109/10408363.2013.863267Search in Google Scholar PubMed
4. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasan RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol 2012;60:1249–56.10.1016/j.jacc.2012.04.053Search in Google Scholar PubMed PubMed Central
5. Pugliese G, Iacobini C, Pesce CM, Menini S. Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 2014;25:136–50.10.1093/glycob/cwu111Search in Google Scholar PubMed
6. Pugliese G, Iacobini C, Ricci C, Blasetti Fantauzzi C, Menini S. Galectin-3 in diabetic patients. Clin Chem Lab Med 2014;52:1413–23.10.1515/cclm-2014-0187Search in Google Scholar PubMed
7. Lippi G, Cervellin G, Sanchis-Gomar F. Galectin-3 in atrial fibrillation: simple bystander, player or both? Clin Biochem 2015;48:818–22.10.1016/j.clinbiochem.2015.04.021Search in Google Scholar PubMed
8. Gurses KM, Yalcin MU, Kocyigit D, Canpinar H, Evranos B, Yorgun H, et al. Effects of persistent atrial fibrillation on serum galectin-3 levels. Am J Cardiol 2015;115:647–51.10.1016/j.amjcard.2014.12.021Search in Google Scholar PubMed
9. Minoretti P, Falcone C, Calcagnino M, Emanuele E, Buzzi MP, Coen E, et al. Prognostic significance of plasma osteopontin levels in patients with chronic stable angina. Eur Heart J 2006;27:802–7.10.1093/eurheartj/ehi730Search in Google Scholar PubMed
10. Ozkan G, Ulusoy S, Mentese A, Guvercin B, Karahan SC, Yavuz A, et al. Can be galectin-3 a novel marker in determining mortality in hemodialysis patients? Clin Biochem 2015;48:768–73.10.1016/j.clinbiochem.2015.05.003Search in Google Scholar PubMed
11. Schelbert EB, Fonarow GC, Bonow RO, Butler J, Gheorghiade M. Therapeutic targets in heart failure: refocusing on the myocardial interstitium. J Am Coll Cardiol 2014;63:2188–98.10.1016/j.jacc.2014.01.068Search in Google Scholar PubMed
12. Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013;6:107–17.10.1161/CIRCHEARTFAILURE.112.971168Search in Google Scholar PubMed
13. Jalife J. Mechanisms of persistent atrial fibrillation. Curr Opin Cardiol 2014;29:20–7.10.1097/HCO.0000000000000027Search in Google Scholar PubMed
14. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012;272:55–64.10.1111/j.1365-2796.2011.02476.xSearch in Google Scholar PubMed
15. Rosenberg M, Zugck C, Nelles M, Juenger C, Frank D, Remppis A, et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ Heart Fail 2008;1:43–9.10.1161/CIRCHEARTFAILURE.107.746172Search in Google Scholar PubMed
16. Singh M, Foster CR, Dalal S, Singh K. Role of osteopontin in heart failure associated with aging. Heart Fail Rev 2010;15:487–94.10.1007/s10741-010-9158-6Search in Google Scholar PubMed
17. Lopez B, Gonzalez A, Lindner D, Westermann D, Ravassa S, Beaumont J, et al. Osteopontin-mediated myocardial fibrosis in heart failure: a role for lysyl oxidase? Cardiovasc Res 2013;99:111–20.10.1093/cvr/cvt100Search in Google Scholar PubMed
18. Kahles F, Findeisen HM, Bruemmer D. Osteopontin: a novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab 2014;3:384–93.10.1016/j.molmet.2014.03.004Search in Google Scholar PubMed PubMed Central
19. Kavukcuoglu NB, Denhardt DT, Guzelsu N, Mann AB. Osteopontin deficiency and aging on nanomechanics of mouse bone. J Biomed Mater Res A 2007;83:136–44.10.1002/jbm.a.31081Search in Google Scholar PubMed
20. Miller SJ, Watson WC, Kerr KA, Labarrere CA, Chen NX, Deeg MA, et al. Development of progressive aortic vasculopathy in a rat model of aging. Am J Physiol Heart Circ Physiol 2007;293:H2634–43.10.1152/ajpheart.00397.2007Search in Google Scholar PubMed
21. Paliwal P, Pishesha N, Wijaya D, Conboy IM. Age dependent increase in the levels of osteopontin inhibits skeletal muscle regeneration. Aging (Albany NY) 2012;4:553–66.10.18632/aging.100477Search in Google Scholar PubMed PubMed Central
22. Uaesoontrachoon K, Yoo HJ, Tudor EM, Pike RN, Mackie EJ, Pagel CN. Osteopontin and skeletal muscle myoblasts: association with muscle regeneration and regulation of myoblast function in vitro. Int J Biochem Cell Biol 2008;40:2303–14.10.1016/j.biocel.2008.03.020Search in Google Scholar PubMed
23. Andersen SL, Sebastiani P, Dworkis DA, Feldman L, Perls TT. Health span approximates life span among many supercentenarians: compression of morbidity at the approximate limit of life span. J Gerontol A Biol Sci Med Sci 2012;67:395–405.10.1093/gerona/glr223Search in Google Scholar PubMed PubMed Central
24. Emanuele E, Minoretti P, Pareja-Galeano H, Sanchis-Gomar F, Garatachea N, Lucia A. Serum irisin levels, precocious myocardial infarction, and healthy exceptional longevity. Am J Med 2014;127:888–90.10.1016/j.amjmed.2014.04.025Search in Google Scholar PubMed
25. Emanuele E, Minoretti P, Sanchis-Gomar F, Pareja-Galeano H, Yilmaz Y, Garatachea N, et al. Can enhanced autophagy be associated with human longevity? Serum levels of the autophagy biomarker beclin-1 are increased in healthy centenarians. Rejuvenation Res 2014;17:518–24.10.1089/rej.2014.1607Search in Google Scholar PubMed
26. Sanchis-Gomar F, Pareja-Galeano H, Santos-Lozano A, Garatachea N, Fiuza-Luces C, Venturini L, et al. A preliminary candidate approach identifies the combination of chemerin, fetuin-A, and fibroblast growth factors 19 and 21 as a potential biomarker panel of successful aging. Age (Dordr) 2015;37:9776.10.1007/s11357-015-9776-ySearch in Google Scholar PubMed PubMed Central
27. Emanuele E, Fontana JM, Minoretti P, Geroldi D. Preliminary evidence of a genetic association between chromosome 9p21.3 and human longevity. Rejuvenation Res 2010;13:23–6.10.1089/rej.2009.0970Search in Google Scholar PubMed
28. Trost SG, Fees BS, Haar SJ, Murray AD, Crowe LK. Identification and validity of accelerometer cut-points for toddlers. Obesity (Silver Spring) 2012;20:2317–9.10.1038/oby.2011.364Search in Google Scholar PubMed
29. Hausman DB, Fischer JG, Johnson MA. Protein, lipid, and hematological biomarkers in centenarians: definitions, interpretation and relationships with health. Maturitas 2012;71:205–12.10.1016/j.maturitas.2011.12.002Search in Google Scholar PubMed
30. Liu YH, D’Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U, et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 2009;296:H404–12.10.1152/ajpheart.00747.2008Search in Google Scholar PubMed PubMed Central
31. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013;33:67–75.10.1161/ATVBAHA.112.300569Search in Google Scholar PubMed
32. Lax A, Sanchez-Mas J, Asensio-Lopez MC, Fernandez-Del Palacio MJ, Caballero L, Garrido IP, et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Fail 2015;3:50–8.10.1016/j.jchf.2014.07.015Search in Google Scholar PubMed
33. Lippi G, Salvagno GL, Bonfanti L, Cervellin G. Relationship between serum galectin-3 values and demographical or biochemical variables in patients without acute coronary syndrome. Int J Cardiol 2014;171:270–1.10.1016/j.ijcard.2013.11.137Search in Google Scholar PubMed
34. Matsui Y, Iwasaki N, Kon S, Takahashi D, Morimoto J, Denhardt DT, et al. Accelerated development of aging-associated and instability-induced osteoarthritis in osteopontin-deficient mice. Arthritis Rheum 2009;60:2362–71.10.1002/art.24705Search in Google Scholar PubMed
35. Comi C, Carecchio M, Chiocchetti A, Nicola S, Galimberti D, Fenoglio C, et al. Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer’s disease and its levels correlate with cognitive decline. J Alzheimers Dis 2010;19:1143–8.10.3233/JAD-2010-1309Search in Google Scholar PubMed
36. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012;92:635–88.10.1152/physrev.00008.2011Search in Google Scholar PubMed PubMed Central
©2016 Walter de Gruyter GmbH, Berlin/Boston
